Answers are grounded in this paper and cite their sources.
Background: Helicobacter pylori (H. pylori) infection remains highly prevalent in Iran, where high antibiotic resistance can limit eradication efficacy. Saccharomyces boulardii (S. boulardii) may improve eradication and treatment tolerability, although evidence remains inconsistent. This trial evaluated adjunctive S. boulardii in a high-prevalence, high-resistance setting. Methods: In this randomized, single-blind, placebo-controlled trial, 218 H. pylori-positive adults received 14 days of PPI, bismuth, amoxicillin, and clarithromycin (P-BAC) plus either S. boulardii (250 mg twice daily) or placebo. The primary outcome was H. pylori eradication assessed 30 days after treatment by stool antigen testing, analyzed by intention-to-treat (ITT) and per-protocol (PP) principles. Treatment-related adverse events were secondary outcomes. Trial registration: Iranian Registry of Clinical Trials, IRCT20230827059280N1. Results: In the PP analysis, eradication was lower with S. boulardii than placebo (65.0% vs. 76.5%; RR = 0.849, 95% CI: 0.709-1.018), with a similar pattern in the ITT analysis (59.6% vs. 68.8%; RR = 0.867, 95% CI: 0.710-1.058). Neither analysis showed a statistically significant difference. Overall adverse events were significantly less frequent with S. boulardii (44.0% vs. 68.4%; RR = 0.644, 95% CI: 0.497-0.834; P < 0.001), with lower rates of bloating (4.0% vs. 23.5%; adjusted P < 0.001) and epigastric pain (4.0% vs. 14.3%; adjusted P = 0.041). Conclusion: Adjunctive S. boulardii did not significantly improve H. pylori eradication with 14-day P-BAC therapy. However, it significantly reduced adverse events, particularly bloating and epigastric pain. Further multicenter trials incorporating individualized susceptibility testing are warranted.
No takes yet. Share an insight, caveat, or question.
Jafari et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: